The multiple faces of glucagon-like peptide-1--obesity, appetite, and stress: what is next? A review.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study.Critical care medicine · 2014
   Trial
2. Therapeutic Effects of Sleeve Gastrectomy and Ileal Transposition on Type 2 Diabetes in a Non-Obese Rat Model by Regulating Blood Glucose and Reducing Ghrelin Levels.Medical science monitor : international medical journal of experimental and clinical research · 2019
   Article
3. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation inOncology letters · 2017
   Article
4. Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration.Journal of clinical biochemistry and nutrition · 2015
   Article
5. Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction.Surgical endoscopy · 2012
   Article
6. Laparoscopic sleeve gastrectomy: a first step for rapid weight loss in morbidly obese patients requiring a second non-bariatric procedure.Obesity surgery · 2012
   Article
7. The changes of pro-opiomelanocortin neurons in type 2 diabetes mellitus rats after ileal transposition: the role of POMC neurons.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2011
   Article
8. Effects of glucagon-like peptide 1 on glycemia control and its metabolic consequence after severe thermal injury--studies in an animal model.Surgery · 2011
   Article
9. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery.JPEN. Journal of parenteral and enteral nutrition · 2011
   Article
10. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review.Journal of the American Dietetic Association · 2010
    Review
11. Sleeve gastrectomy provides a better control of diabetes by decreasing ghrelin in the diabetic Goto-Kakizaki rats.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2009
    Article
12. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides.The Journal of clinical endocrinology and metabolism · 2009
    Review
13. Analysis of the results of sleeve gastrectomy for morbid obesity and the role of ghrelin.Surgery today · 2008
    Review
14. Laparoscopic vertical sleeve gastrectomy for morbid obesity. The future procedure of choice?Surgery today · 2007
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as